Cytosorbents (CTSO) Q3 2026 Earnings Report

The call was predominantly positive. The company achieved operating cash flow breakeven, substantially improved gross margin and adjusted EBITDA, reduced operating costs and cash usage, and reported progress in rebuilding commercial capacity and advancing DrugSorb-ATR and HemoDefend-BGA. The principal challenges were the approximately 20%-21% decline in Germany, a higher nine-month net loss caused by a non-cash foreign currency swing, the possibility of future quarters with modest cash burn, outstanding Nasdaq and debt-restructuring requirements, and uncertainty around regulatory approval and timing.

Management is targeting product gross margins consistently in the mid-70% range and expects to remain at or near operating cash flow break-even, while noting that break-even will not be a straight line, every quarter will not be positive, and some quarters may show a modest burn and others a modest positive cash flow; it is actively working to satisfy the remaining Nasdaq listing requirement and debt restructuring by the end of this year, plans to add another German sales representative next month and two more by early 2027, expects a new BRILINTA De Novo submission in early 2027 subject to necessary work and regulatory interactions with a decision by FDA 150 days later, expects a separate Eliquis and Xarelto submission in 2027, and estimates an initial U.S. and Canadian addressable market of approximately $300 million to start, potentially expanding to $1 billion- $2 billion.